Ohmori F, Tachibana T
Department of Medicine, Osaka Prefecture Hospital.
Nihon Rinsho. 1994 Jun;52(6):1648-53.
Corticosteroid treatment of cardiac sarcoidosis is not conclusive, although sarcoid granulomas in the heart may be more responsive to steroid therapy than in other organs. Healing of sarcoidosis lesions in the heart results in fibrosis and sinning of the myocardium, which may lead to aneurysm formation causing congestive heart failure or sudden death. Congestive heart failure is the leading cause of death in patients with cardiac sarcoidosis in Japan. It is reasonable to initiate steroid therapy as soon as the diagnosis of cardiac sarcoidosis is established in order to prevent fibrosis. Early initiation of steroid therapy with conventional treatment for specific cardiac manifestations (antiarrhythmic therapy, pacemaker implantation and heart failure medication) should bring improvement in the left ventricular systolic and diastolic function with prevention from malignant arrhythmias. Systemic disorder represents a contraindication to organ transplantation, but heart transplantation is now a feasible treatment for patients with end-stage cardiac sarcoidosis with congestive heart failure.
尽管心脏中的结节病肉芽肿可能比其他器官中的对类固醇治疗更敏感,但皮质类固醇治疗心脏结节病的效果尚无定论。心脏结节病病变的愈合会导致心肌纤维化和瘢痕形成,这可能会导致动脉瘤形成,进而引起充血性心力衰竭或猝死。在日本,充血性心力衰竭是心脏结节病患者的主要死因。一旦确诊心脏结节病,为预防纤维化,尽早开始类固醇治疗是合理的。早期开始使用类固醇治疗并结合针对特定心脏表现的常规治疗(抗心律失常治疗、起搏器植入和心力衰竭药物治疗)应能改善左心室收缩和舒张功能,并预防恶性心律失常。全身性疾病是器官移植的禁忌症,但心脏移植目前是终末期充血性心力衰竭心脏结节病患者的一种可行治疗方法。